Reality is the best data on this actually comes from the short-term trials. So the short-term, you know, aspirin, clopidogrel versus aspirin trials, so that’s POINT and CHANCE, but also TALOS, which was clopidogrel and aspirin versus aspirin alone, and also CHANCE-2, which was ticagrelor versus clopidogrel on the background of aspirin. So in all those trials, what you see is the impact of dual-antiplatelet therapy is very quick...
Reality is the best data on this actually comes from the short-term trials. So the short-term, you know, aspirin, clopidogrel versus aspirin trials, so that’s POINT and CHANCE, but also TALOS, which was clopidogrel and aspirin versus aspirin alone, and also CHANCE-2, which was ticagrelor versus clopidogrel on the background of aspirin. So in all those trials, what you see is the impact of dual-antiplatelet therapy is very quick. So it’s within the first week, maybe persist through three weeks. And that’s what we did a sort of subset, a more detailed study of the time periods in the POINT trial. And the efficacy really was concentrated in the first three weeks. There really wasn’t a signal for efficacy out to 90 days. So from those trials, it looks like it works really well in that early period and not so well in a delayed period. That’s one thing and the other trials suggest that as well, it’s just as risky in the early period as in the delayed period, so if you’re continuing on beyond when it works, then you’re just getting bleeding risk without benefits, and so probably that 21 days from the short-term trials feels like it’s going to be the right one. All the long-term trials that we’ve ever done, none of them has demonstrated that dual-antiplatelet therapy is worth the risk of hemorrhage that it produces. In fact, many of them haven’t shown any impact on ischemic events. So not indicated for really any indication after that acute period.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.